Advertisement

European Journal of Nutrition

, Volume 58, Issue 1, pp 271–280 | Cite as

Coffee consumption and risk of hypertension: a dose–response meta-analysis of prospective studies

  • Lanfranco D’EliaEmail author
  • Ersilia La Fata
  • Ferruccio Galletti
  • Luca Scalfi
  • Pasquale Strazzullo
Original Contribution

Abstract

Purpose

Recently, a large prospective study provided additional information concerning the debated possible association between habitual coffee consumption and risk of hypertension (HPT). Therefore, we updated the state of knowledge on this issue by carrying out a comprehensive new systematic review of the literature and a meta-analysis of the available relevant studies.

Methods

We performed a systematic search for prospective studies on general population, published without language restrictions (1966–August 2017). A random-effects dose–response meta-analysis was conducted to combine study specific relative risks (RRs) and 95% confidence intervals. Potential non-linear relation was investigated using restricted cubic splines.

Results

Four studies (196,256 participants, 41,184 diagnosis of HPT) met the inclusion criteria. Coffee intake was assessed by dietary questionnaire. Dose–response meta-analysis showed a non-linear relationship between coffee consumption and risk of HPT (p for non-linearity < 0.001). Whereas the habitual drinking of one or two cups of coffee per day, compared with non-drinking, was not associated with risk of HPT, a significantly protective effect of coffee consumption was found starting from the consumption of three cups of coffee per day (RR = 0.97, 95% CI = 0.94 to 0.99), and was confirmed for greater consumption.

Conclusions

The results of this analysis indicate that habitual moderate coffee intake is not associated with higher risk of HPT in the general population and that in fact a non-linear inverse dose–response relationship occurs between coffee consumption and risk of HPT.

Keywords

Coffee Hypertension Blood pressure Dose–response meta-analysis 

Notes

Author contributions

LD conceived the study aims and design, contributed to the systematic review and to the data extraction, performed the analysis, interpreted the results, and drafted the manuscript. ELF contributed to the systematic review and to the data extraction, contributed to interpretation of results, and drafted the manuscript. LS contributed to the preparation of revised version of the manuscript. FG contributed to the systematic review and to interpretation of results, and drafted the manuscript. PS contributed to the systematic review, interpretation of results and drafted the manuscript.

Compliance with ethical standards

Funding sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Supplementary material

394_2017_1591_MOESM1_ESM.doc (76 kb)
Supplementary material 1 (DOC 76 KB)

References

  1. 1.
    International Coffee Organization 2017. http://www.ico.org/prices/new-consumption-table.pdf. Accessed Sept 19, 2017
  2. 2.
    USA NCA (2012) National coffee drinking trends. National Coffee Association USA, New YorkGoogle Scholar
  3. 3.
    http://www.euromonitor.com. Accessed Sept 19, 2017
  4. 4.
    Ding M, Satija A, Bhupathiraju SN, Hu Y, Sun Q, Han J, Lopez-Garcia E, Willett W, van Dam RM, Hu FB (2015) Association of coffee consumption with total and cause-specific mortality in 3 large prospective cohorts. Circulation 132(24):2305–2315CrossRefGoogle Scholar
  5. 5.
    Crippa A, Discacciati A, Larsson SC, Wolk A, Orsini N (2014) Coffee consumption and mortality from all causes, cardiovascular disease, and cancer: a dose-response meta-analysis. Am J Epidemiol 180(8):763–775CrossRefGoogle Scholar
  6. 6.
    Ding M, Bhupathiraju SN, Satija A, van Dam RM, Hu FB (2014) Long-term coffee consumption and risk of cardiovascular diseases. A systematic review and dose-response meta-analysis of prospective cohort studies. Circulation 129:643–659CrossRefGoogle Scholar
  7. 7.
    Larsson SC, Orsini N (2011) Coffee consumption and risk of stroke: a dose-response meta-analysis. Am J Epidemiol 174:993–1001CrossRefGoogle Scholar
  8. 8.
    Lewington S, Clarke R, Qizilbash N, Peto R, Collins R (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903–1913CrossRefGoogle Scholar
  9. 9.
    World Health Organization. A global brief on hypertension: silent killer, global public health crisis. http://apps.who.int/iris/bitstream/10665/79059/WHO_DCO_WHD_2013.2_eng.pdf. Accessed 19 Sept 2017
  10. 10.
    Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J (2016) Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 134(6):441–450CrossRefGoogle Scholar
  11. 11.
    Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J (2005) Global burden of hypertension: analysis of worldwide data. The Lancet 365:217–223CrossRefGoogle Scholar
  12. 12.
    Nussberger J, Mooser V, Maridor G, Juillerat L, Waeber B, Brunner HR (1990) Caffeine-induced diuresis and atrial natriuretic peptides. J Cardiovasc Pharmacol 15:685–691CrossRefGoogle Scholar
  13. 13.
    Suzuki A, Yamamoto N, Jokura H, Yamamoto M, Fujii A, Tokimitsu I, Saito I (2006) Chlorogenic acid attenuates hypertension and improves endothelial function in spontaneously hypertensive rats. J Hypertens 24:1065–1073CrossRefGoogle Scholar
  14. 14.
    Park JB (2013) Isolation and quantification of major chlorogenic acids in three major instant coffee brands and their potential effects on H2O2-induced mitochondrial membrane depolarization and apoptosis in PC-12 cells. Food Funct 4:1632–1638CrossRefGoogle Scholar
  15. 15.
    Nurminen ML, Niittynen L, Korpela R, Vapaatalo H (1999) Coffee, caffeine and blood pressure: a critical review. Eur J Clin Nutr 53:831–839CrossRefGoogle Scholar
  16. 16.
    Mesas AE, Leon-Muñoz LM, Rodriguez-Artalejo F, Lopez-Garcia E (2011) The effect of coffee on blood pressure and cardiovascular disease in hypertensive individuals: a systematic review and meta-analysis. Am J Clin Nutr 94(4):1113–1126CrossRefGoogle Scholar
  17. 17.
    Rhee JJ, Qin F, Hedlin HK, Chang TI, Bird CE, Zaslavsky O, Manson JE, Stefanick ML, Winkelmayer WC (2016) Coffee and caffeine consumption and the risk of hypertension in postmenopausal women. Am J Clin Nutr 103(1):210–217CrossRefGoogle Scholar
  18. 18.
    Winkelmayer WC, Stampfer MJ, Willett WC, Curhan GC (2005) Habitual caffeine intake and the risk of hypertension in women. JAMA 294:2330–2335CrossRefGoogle Scholar
  19. 19.
    Zhang Z, Hu G, Caballero B, Appel L, Chen L (2011) Habitual coffee consumption and risk of hypertension: a systematic review and meta-analysis of prospective observational studies. Am J Clin Nutr 93:1212–1219CrossRefGoogle Scholar
  20. 20.
    Steffen M, Kuhle C, Hensrud D, Erwin PJ, Murad MH (2012) The effect of coffee consumption on blood pressure and the development of hypertension: a systematic review and meta-analysis. J Hypertens 30:2245–2254CrossRefGoogle Scholar
  21. 21.
    Palatini P, Dorigatti F, Santonastaso M, Cozzio S, Biasion T, Garavelli G, Pessina AC, Mos L (2007) Association between coffee consumption and risk of hypertension. Ann Med 39(7):545–553CrossRefGoogle Scholar
  22. 22.
    Uiterwaal CS, Verschuren WM, Bueno-de-Mesquita HB, Ocké M, Geleijnse JM, Boshuizen HC, Peeters PH, Feskens EJ, Grobbee DE (2007) Coffee intake and incidence of hypertension. Am J Clin Nutr 85(3):718 – 23Google Scholar
  23. 23.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRefGoogle Scholar
  24. 24.
    Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accesed 11 July 2016
  25. 25.
    Greenland S, Longnecker MP (1992) Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 135:1301–1309CrossRefGoogle Scholar
  26. 26.
    Orsini N, Bellocco R, Greenland S (2006) Generalized least squares for trend estimation of summarized dose-response data. Stata J 6:40–57CrossRefGoogle Scholar
  27. 27.
    Desquilbet L, Mariotti F (2010) Dose-response analyses using restricted cubic spline functions in public health research. Stat Med 29(9):1037–1057Google Scholar
  28. 28.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefGoogle Scholar
  29. 29.
    Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duval S, Altman DG, Moher D, Higgins JP (2011) Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomized controlled trials. BMJ 342:d4002CrossRefGoogle Scholar
  30. 30.
    Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR (2000) Empirical assessment of effect of publication bias on meta-analyses. BMJ 320:1574–1577CrossRefGoogle Scholar
  31. 31.
    Hu G, Jousilahti P, Nissinen A, Bidel S, Antikainen R, Tuomilehto J (2007) Coffee consumption and the incidence of antihypertensive drug treatment in Finnish men and women. Am J Clin Nutr 86:457–464CrossRefGoogle Scholar
  32. 32.
    Klag MJ, Wang NY, Meoni LA, Brancati FL, Cooper LA, Liang KY, Young JH, Ford DE (2002) Coffee intake and risk of hypertension: the Johns Hopkins precursors study. Arch Intern Med 162:657–662CrossRefGoogle Scholar
  33. 33.
    Grosso G, Stepaniak U, Polak M, Micek A, Topor-Madry R, Stefler D, Szafraniec K, Pajak A (2016) Coffee consumption and risk of hypertension in the Polish arm of the HAPIEE cohort study. Eur J Clin Nutr 70(1):109–115CrossRefGoogle Scholar
  34. 34.
    Chei CL, Loh JK, Soh A, Yuan JM, Koh WP (2017) Coffee, tea, caffeine, and risk of hypertension: the Singapore Chinese Health Study. Eur J Nutr.  https://doi.org/10.1007/s00394-017-1412-4 Google Scholar
  35. 35.
    Marventano S, Salomone F, Godos J, Pluchinotta F, Del Rio D, Mistretta A, Grosso G (2016) Coffee and tea consumption in relation with non-alcoholic fatty liver and metabolic syndrome: a systematic review and meta-analysis of observational studies. Clin Nutr 35:1269–1281CrossRefGoogle Scholar
  36. 36.
    Bosire C, Stampfer MJ, Subar AF, Wilson KM, Park Y, Sinha R (2013) Coffee consumption and the risk of overall and fatal prostate cancer in the NIH-AARP Diet and Health Study. Cancer Causes Control 24(8):1527–1534CrossRefGoogle Scholar
  37. 37.
    Wilson KM, Bälter K, Möller E, Adami HO, Andrén O, Andersson SO, Grönberg H, Mucci LA (2013) Coffee and risk of prostate cancer incidence and mortality in the Cancer of the Prostate in Sweden Study. Cancer Causes Control 24(8):1575–1581CrossRefGoogle Scholar
  38. 38.
    Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, Rosner B, Hennekens CH, Speizer FE (1986) Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol 123:894–900CrossRefGoogle Scholar
  39. 39.
    Godos J, Pluchinotta FR, Marventano S, Buscemi S, Li Volti G, Galvano F, Grosso G (2014) Coffee components and cardiovascular risk: beneficial and detrimental effects. Int J Food Sci Nutr 21:1–12Google Scholar
  40. 40.
    Myers MG (1988) Effects of caffeine on blood pressure. Arch Intern Med 148:1189–1193CrossRefGoogle Scholar
  41. 41.
    Shi J, Benowitz NL, Denaro CP, Sheiner LB (1993) Pharmacokinetic-pharmacodynamic modeling of caffeine: tolerance to pressor effects. Clin Pharmacol Ther 53:6–14CrossRefGoogle Scholar
  42. 42.
    Passmore AP, Kondowe GB, Johnston GD (1987) Renal and cardiovascular effects of caffeine: a dose-response study. Clin Sci (Lond) 72:749–756CrossRefGoogle Scholar
  43. 43.
    Wilcox CS, Welch WJ, Schreiner GF, Belardinelli L (1999) Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J Am Soc Nephrol 10:714–720Google Scholar
  44. 44.
    Rieg T, Steigele H, Schnermann J, Richter K, Osswald H, Vallon V (2005) Requirement of intact adenosine A1 receptors for the diuretic and natriuretic action of the methylxanthines theophylline and caffeine. J Pharmacol Exp Ther 313:403–409CrossRefGoogle Scholar
  45. 45.
    van Buren M, Bijlsma JA, Boer P, van Rijn HJ, Koomans HA (1993) Natriuretic and hypotensive effect of adenosine-1 blockade in essential hypertension. Hypertension 22:728–734CrossRefGoogle Scholar
  46. 46.
    Knight RJ, Bowmer CJ, Yates MS (1993) The diuretic action of 8-cyclopentyl-1,3-dipropylxanthine, a selective A1 adenosine receptor antagonist. Br J Pharmacol 109:271–277CrossRefGoogle Scholar
  47. 47.
    Li PG, Xu JW, Ikeda K, Kobayakawa A, Kayano Y, Mitani T, Ikami T, Yamori Y (2005) Caffeic acid inhibits vascular smooth muscle cell proliferation induced by angiotensin II in stroke-prone spontaneously hypertensive rats. Hypertens Res 28:369–377CrossRefGoogle Scholar
  48. 48.
    Actis-Goretta L, Ottaviani JI, Fraga CG (2006) Inhibition of angiotensin converting enzyme activity by flavanol-rich foods. J Agric Food Chem 54:229–234CrossRefGoogle Scholar
  49. 49.
    Ohsaki Y, Shirakawa H, Koseki T, Komai M (2008) Novel effects of a single administration of ferulic acid on the regulation of blood pressure and the hepatic lipid metabolic profile in stroke-prone spontaneously hypertensive rats. J Agric Food Chem 56:2825–2830CrossRefGoogle Scholar
  50. 50.
    Suzuki A, Fujii A, Yamamoto N, Yamamoto M, Ohminami H, Kameyama A, Shibuya Y, Nishizawa Y, Tokimitsu I, Saito I (2006) Improvement of hypertension and vascular dysfunction by hydroxyhydroquinone-free coffee in a genetic model of hypertension. FEBS Lett 580:2317–2322CrossRefGoogle Scholar
  51. 51.
    Suzuki A, Kagawa D, Fujii A, Ochiai R, Tokimitsu I, Saito I (2002) Short- and long-term effects of ferulic acid on blood pressure in spontaneously hypertensive rats. Am J Hypertens 15:351–357CrossRefGoogle Scholar
  52. 52.
    Suzuki A, Yamamoto M, Jokura H, Fujii A, Tokimitsu I, Hase T, Saito I (2207) Ferulic acid restores endothelium-dependent vasodilation in aortas of spontaneously hypertensive rats. Am J Hypertens 20:508–513CrossRefGoogle Scholar
  53. 53.
    Diaz-Rubio ME, Saura-Calixto F (2007) Dietary fiber in brewed coffee. J Agric Food Chem 55:1999–2003CrossRefGoogle Scholar
  54. 54.
    Streppel MT, Arends LR, van’t Veer P, Grobbee DE, Geleijnse JM (2005) Dietary fiber and blood pressure: a meta-analysis of randomized placebo-controlled trials. Arch Intern Med 165(2):150–156CrossRefGoogle Scholar
  55. 55.
    Kiyohara C, Kono S, Honjo S, Todoroki I, Sakurai Y, Nishiwaki M, Hamada H, Nishikawa H, Koga H, Ogawa S, Nakagawa K (1999) Inverse association between coffee drinking and serum uric acid concentrations in middle-aged Japanese males. Br J Nutr 82:125–130Google Scholar
  56. 56.
    Choi HK, Curhan G (2007) Coffee, tea, and caffeine consumption and serum uric acid level: the third national health and nutrition examination survey. Arthritis Rheum 57(5):816–821CrossRefGoogle Scholar
  57. 57.
    Pham NM, Yoshida D, Yoshida M, Yin G, Toyomura K, Ohnaka K, Takayanagi R, Kono S (2010) The relation of coffee consumption to serum uric Acid in Japanese men and women aged 49–76 years. J Nutr Metab 2010:930757.  http://dx.doi.org/10.1155/2010/930757 CrossRefGoogle Scholar
  58. 58.
    Borghi C, Agabiti Rosei E, Bardin T, Dawson J, Dominiczak A, Kielstein JT, Manolis AJ, Perez-Ruiz F, Mancia G (2015) Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 33:1729–1741CrossRefGoogle Scholar
  59. 59.
    Arnlov J, Vessby B, Riserus U (2004) Coffee consumption and insulin sensitivity. JAMA 291(10):1199–1201CrossRefGoogle Scholar
  60. 60.
    Wu T, Willett WC, Hankinson SE, Giovannucci E (2005) Caffeinated coffee, decaffeinated coffee, and caffeine in relation to plasma C-peptide levels, a marker of insulin secretion, in U.S. women. Diabetes Care 28(6):1390–1396CrossRefGoogle Scholar
  61. 61.
    Hanhineva K, Törrönen R, Bondia-Pons I, Pekkinen J, Kolehmainen M, Mykkänen H, Poutanen K (2010) Impact of dietary polyphenols on carbohydrate metabolism. Int J Mol Sci 11(4):1365–1402CrossRefGoogle Scholar
  62. 62.
    Johnston KL, Clifford MN, Morgan LM (2003) Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. Am J Clin Nutr 78(4):728–733CrossRefGoogle Scholar
  63. 63.
    van Dijk AE, Olthof MR, Meeuse JC, Seebus E, Heine RJ, van Dam RM (2009) Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance. Diabetes Care 32:1023–1025CrossRefGoogle Scholar
  64. 64.
    Zhou J, Zhou S, Zeng S (2011) Experimental diabetes treated with trigonelline: effect on b-cell, Fundam. Clin Pharmacol 27:279–287Google Scholar
  65. 65.
    Hamden K, Bengara A, Amri Z, Elfeki A (2013) Experimental diabetes treated with trigonelline: effect on key enzymes related to diabetes and hypertension, b-cell and liver function. Mol Cell Biochem 381(1–2):85–94CrossRefGoogle Scholar
  66. 66.
    Ghule AE, Jadhav SS, Bodhankar SL (2012) Trigonelline ameliorates diabetic hypertensive nephropathy by suppression of oxidative stress in kidney and reduction in renal cell apoptosis and fibrosis in streptozotocin induced neonatal diabetic (nSTZ) rats. Int Immunopharmacol 14(4):740–748CrossRefGoogle Scholar
  67. 67.
    Kim J, Kim J, Shim S, Lee CY, Lee KW, Lee HJ (2014) Cocoa phytochemicals: recent advances in molecular mechanisms on health. Crit Rev Food Sci Nutr 54:1458–1472CrossRefGoogle Scholar
  68. 68.
    Grassi D, Desideri G, Ferri C (2013) Protective effects of dark chocolate on endothelial function and diabetes. Curr Opin Clin Nutr Metab Care 16:662–668CrossRefGoogle Scholar
  69. 69.
    Buitrago-Lopez A, Sanderson J, Johnson L, Warnakula S, Wood A, Di Angelantonio E, Franco OH (2011) Chocolate consumption and cardiometabolic disorders: systematic review and meta-analysis. Brit Med J 343:4488–4495CrossRefGoogle Scholar
  70. 70.
    Lopez-Garcia E, van Dam RM, Rajpathak S, Willett WC, Manson JE, Hu FB (2006) Changes in caffeine intake and long-termweight change in men and women. Am J Clin Nutr 83(3):674–680CrossRefGoogle Scholar
  71. 71.
    Greenberg JA, Axen KV, Schnoll R, Boozer CN (2005) Coffee, tea and diabetes: the role of weight loss and caffeine. Int J Obes (Lond) 29(9):1121–1129CrossRefGoogle Scholar
  72. 72.
    Zheng G, Sayam K, Okubo T, Juneja LR, Oguni I (2004) Anti-obesity effects of three major components of green tea, catechins, caffeine and theanine, in mice. In Vivo 18:55–62Google Scholar
  73. 73.
    Cheung WT, Lee CM, Ng TB (1988) Potentiation of the antioipolytic effect of 2-chloroadenosine after chronic caffeine treatment. Pharmacology 36:331–339CrossRefGoogle Scholar
  74. 74.
    Watanabe T, Arai Y, Mitsui Y, Kusaura T, Okawa W, Kajihara Y, Saito I (2006) The blood pressure-lowering effect and safety of chlorogenic acid from green coffee bean extract in essential hypertension. Clin Exp Hypertens 28:439–449CrossRefGoogle Scholar
  75. 75.
    Yamaguchi T, Chikama A, Mori K, Watanabe T, Shioya Y, Katsuragi Y, Tokimitsu I (2008) Hydroxyhydroquinone-free coffee: a double-blind, randomized controlled dose-response study of blood pressure. Nutr Metab Cardiovasc Dis 18:408–414CrossRefGoogle Scholar
  76. 76.
    Gniechwitz D, Brueckel B, Reichardt N, Blaut M, Steinhart H, Bunzel M (2007) Coffee dietary fiber contents and structural characteristics as influenced by coffee type and technological and brewing procedures. J Agric Food Chem 56:11027–11034CrossRefGoogle Scholar
  77. 77.
    Guessous I, Dobrinas M, Kutalik Z, Pruijm M, Ehret G, Maillard M, Bergmann S, Beckmann JS, Cusi D, Rizzi F, Cappuccio F, Cornuz J, Paccaud F, Mooser V, Gaspoz JM, Waeber G, Burnier M, Vollenweider P, Eap CB, Bochud M (2012) Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension. Hum Mol Genet 21:3283–3292CrossRefGoogle Scholar
  78. 78.
    Djordjevic N, Ghotbi R, Bertilsson L, Jankovic S, Aklillu E (2008) Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol 64:381–385CrossRefGoogle Scholar
  79. 79.
    Kalow W, Tang BK (1991) Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49:44–48CrossRefGoogle Scholar
  80. 80.
    Zhou SF, Yang LP, Zhou ZW, Liu YH, Chan E (2009) Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. AAPS J 11:481–494CrossRefGoogle Scholar
  81. 81.
    Fulgoni VL, Keast DR, Lieberman HR (2015) Trends in intake and sources of caffeine in the diets of US adults: 2001–2010. Am J Clin Nutr 101:1081–1087CrossRefGoogle Scholar
  82. 82.
    Popkin BM, Armstrong LE, Bray GM, Caballero B, Frei B, Willett WC (2006) A new proposed guidance system for beverage consumption in the United States. Am J Clin Nutr 83:529–542CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of Clinical Medicine and Surgery, ESH Excellence Center of Hypertension“Federico II” University of Naples Medical SchoolNaplesItaly
  2. 2.Department of Public Health“Federico II” University of Naples Medical SchoolNaplesItaly

Personalised recommendations